The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 12, 2026
Filed:
Sep. 02, 2020
Institut Curie, Paris, FR;
Mnemo Therapeutics, Paris, FR;
Institut National DE LA Sante ET DE LA Recherche Medicale, Paris, FR;
Sebastian Amigorena, Paris, FR;
Marianne Burbage, Paris, FR;
Alexandre Houy, Vitry sur Seine, FR;
Marc-Henri Stern, Paris, FR;
Joshua Waterfall, Paris, FR;
Benjamin Sadacca, Paris, FR;
Antonela Merlotti Ippolito, Paris, FR;
Yago Arribas De Sandoval, Paris, FR;
INSTITUT CURIE, Paris, FR;
MNEMO THERAPEUTICS, Paris, FR;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris, FR;
Abstract
The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: —a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and—a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.